Aurobindo
Pharma Limited
3Q
2013-14 Unaudited Results
Consolidated Financials
during
Q3FY2013-14 on Y-o-Y basis:
• Total Operating Income up by 36.3% to Rs.2140.6Cr (Rs.1570.1Cr)
• Operating Profit (EBIDTA) before Fx improves
to 30.1% (16.5%)
• Operating Profit (EBIDTA) before Fx up 148.5%
to Rs.643.8Cr (Rs.259.1Cr)
• PBT before Fx up by 220.7% to Rs.547.7Cr (Rs.170.8Cr)
• PAT up by 354.8% to Rs.417.5Cr (Rs.91.8Cr)
• Basic & diluted EPS (not annualized) is Rs.14.34
and Rs.14.32 respectively for the
current quarter.
• Formulation Sales up by 57.5% to Rs.1436.1 Cr (Rs.911.8 Cr)
• API Sales up by 12.8% to Rs.744.5 Cr (Rs.660.2
Cr)
• Formulations Sales constitute 65.9% (58.0%)
and API 34.1% (42.0%) of gross sales
The EBITDA during the quarter has improved by
13.6% on Y-o-Y basis due to improved business mix resulting in decrease in
materials consumption, staff costs other expenses to net sales by 9.1%, 0.9%
and 5.6% respectively and decline in dossier income by 2.0%
Commenting on the Company’s
performance, Mr. N. Govindarajan, MD of
the company said:
“We have had a robust
quarter driven by our sustaining base business along with successful launches
in US, translating into better top and bottom line We are confident to sustain
the momentum as we foray into strengthening our access into markets, products
and technology platforms where we are not dominantly present as we consolidate
on our existing businesses”
Global Regulatory
Filings
Filings Q3 FY13-14 :: Cumulative Filings
ANDAs (USA) 14
308
DMFs (USA) 1
176
Formulations Dossiers in other key advanced markets
(incl. Multiple registration into
EU. South Africa, Australia and Canada)81 1940
API DMF/COS filings in other key regulated markets ::28 :: 2214
Patents
6 551
Following approvals in USA (188 cumulative
approvals including 25 tentative by USFDA), South Africa (66 cumulative approvals
by MCC-SA), Australia (47 cumulative approvals by TGA) and Canada (45
cumulative approvals by Health Canada)) were received during the quarter ended
31st December 2013:
USA
1. Acyclovir Sodium Injection 500mg/10mL
(50mg/mL) & 1000mg/20mL (50mg/mL) (Treatment of Herpes, Shingles): Final
2. Bupivacaine Hydrochloride Injection USP
0.25% (2.5mg/mL), 0.5% (5mg/mL) & 0.75% (7.5mg/mL) (Anesthetic): Final
3. Finasteride Tablets USP 1mg (Benign
prostatic hyperplasia): Final (Earlier TA)
4. Lamivudine+Tenofovir Disoproxil Fumarate
Tablets, Co-packaged with Nevirapine Tablets USP 300mg/300mg/200mg (ARV): Final
5. Dextroamphetamine Saccharate, Amphetamine
Aspartate, Dextroamphetamine Sulfate & Amphetamine Sulfate Tablets 5mg,
7.5mg,
10mg, 12.5mg, 15mg, 20mg & 30mg (ADHD
and Narcolepsy): Final
6. Duloxetine Hydrochloride Delayed Release
Capsules 20mg, 30mg & 60mg (CNS): Final
South Africa
1. Fluconazole Capsules 50mg, 100mg, 150mg,
200mg
2. Escitalopram Oxalate Tablets 5mg, 10mg,
20mg
Australia
1. Candesartan/Hydrochlorothiazide Tablets
16/12.5mg, 32/12.5mg and 32/25mg
Canada
1. Sildenafil Tablets 25mg, 50mg, 100mg
2. Valsartan Tablets 40mg, 80mg, 160mg, 320mg
3. Lamivudine/Zidovudine Tablets 150/300mg
4. Pantoprazole Gastro Resistant Tablets 40mg
5. Clopidogrel Tablets 75mg
6. Efavirenz Tablets 600mg
About Aurobindo Pharma
Limited:
Aurobindo Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures generic pharmaceuticals and
active pharmaceutical ingredients. The company’s manufacturing facilities are
approved by several leading regulatory agencies like US FDA, UK MHRA, Japan
PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company’s robust
product portfolio is spread over 6
major therapeutic/product areas encompassing
Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics,
supported by an outstanding R&D set-up. The Company is marketing these
products globally, in over 125 countries.
* * * E N D * * *
No comments:
Post a Comment